Genmab — Juni 2017
-
conjugates (ADC), including peripheral neuropathy and neutropenia. Additionally, conjunctivitis was identified as a tisotumab vedotin specific toxicity, which led to introducing of prophylactic management. In the cervical cancer cohort, 15 patients experienced one or more Grade 3 adverse events: gastro-intestinal related (5 patients), anemia (2 patients), infections (1 patient), neuropathy (2 patients), bleeding (2 patients), other (10 patients).
-
waaaad!? - nye kliniske data fra GEN!
-
mon det er trigger til at SGEN skal bestemme sig?
-
Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study
Company Announcement Preliminary data shows responses achieved in 11 of 34 evaluable patients with cervical cancer treated with tisotumab...
GlobeNewswire News Room (globenewswire.com)
-
ingen usædvanlig tox i studiet
-
I am not 100% sure this is the correct place to watch on FDA site, but this was just updated to inclued 16 June and Dara is not there https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind